Pulmonary Arterial Hypertension Market is estimated to expand at a CAGR of 5.2% from 2022 to 2030.
Pulmonary Arterial Hypertension Industry Overview The global pulmonary arterial hypertension market size is anticipated to reach USD 11.0 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a lucrative CAGR of 5.2% from 2022 to 2030. The key factors driving the market growth include the increasing prevalence of pulmonary arterial hypertension, drug development and technological advancements, product approvals, and initiatives by key companies. Pulmonary Arterial Hypertension Market Segmentation Grand View Research has segmented the pulmonary arterial hypertension market on the basis of drug class, type, route of administration, and region: Based on the Drug Class Insights , the market is segmented into Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs and SGC Stimulators. The prostacyclin and prostacyclin analogs segment dominated the market and...